HK Stock Market Move | CONSUN PHARMA (01681) soared over 11% after earnings report, with its interim profit attributable to shareholders increasing by nearly 20% year-on-year. The sales of its nephrology series products maintain industry leadership.

CONSUN PHARMA (01681) rose over 11% after its performance announcement, and as of the time of writing, it is up 7.24%, trading at HKD 14.37, with a transaction volume of HKD 84.1281 million. In news, on August 26, CONSUN PHARMA announced its results for the six months ending June 30, 2026. The group achieved revenue of RMB 1.785 billion, an increase of 13.8% year-on-year; the profit attributable to equity shareholders was RMB 595 million, up 19.5% year-on-year; basic earnings per share was RMB 0.71; and a mid-term dividend of HKD 0.38 per share is proposed. In the first half of 2026, the group's gross profit was RMB 1.452 billion, compared to RMB 1.209 billion in the same period of 2025, marking a growth of approximately 20.1%. The increase in gross profit was mainly due to sales growth. By product category, sales of nephrology products grew by approximately 18.1% compared to the same period in 2025, maintaining a leading market position. Sales of women's and children's products, as well as liver and gallbladder products, increased by approximately 9.1% and 233.7%, respectively. The overall revenue growth of the group is mainly attributed to its ongoing efforts to expand its national sales network and enhance the market coverage of its products.